To examine the pharmaceutical application of Fourier transform (FT)-Raman spectroscopy, the state of active pharmaceutical ingredients (APIs) in a preparation of several forms was evaluated by investigating the Raman diŠer-ence spectra between the preparation and excipient. The diŠerence spectra indicated that APIs in alacepril tablets, caŠeine sustained-release granules, and quinidine sulfate granules remained unchanged after the manufacturing process. However, the state of spar‰oxacin in nanoparticles changed, although it remained unchanged in tablets or powders. These results show that the FT-Raman diŠerence spectrum is expected to be utilized in theˆeld of quality control of crystalline pharmaceutical preparations.
INTRODUCTION
An active pharmaceutical ingredient (API) in a preparation may change the crystalline condition or phase, or interact with excipients during the manufacturing process involving application of solvent heat, pressure, etc. Such a change in state may be critical if it aŠects the bioavailability of the active ingredient. 1, 2) The crystalline condition of an API(s) in a preparation is generally examined by well known methods including powder X-ray diŠractometry, infrared absorption spectrometry, and thermal analysis which are described in the Japanese Pharmacopoeia XV (JP 15). However, they are all destructive analyses, and the destruction process may sometimes result in a change in the state of an API in a preparation. Furthermore, in some cases, it is impossible to obtain useful information about the state of APIs with these methods due to the eŠects of excipients. With Raman spectroscopy, a preparation can be analyzed as it is, and thus the physicochemical conditions of APIs in the preparation remain unchanged. In addition, Fourier transform (FT)-Raman spectroscopy is currently used for the quantitative determination of APIs [3] [4] [5] or the investigation of crystal polymorphism or amorphism of tablets. 6, 7) In addition, Raman diŠerence spectra are used to elucidate small structural diŠerences in complex substances such as DNA and bisphenol-A-polycarbonate. [8] [9] [10] [11] Raman spectroscopy, a nondestructive analytical method, can be classiˆed broadly into laser Raman spectroscopy, which uses ultraviolet or visible light, and FT-Raman spectroscopy, which uses near-infrared light. 12) Thus, when the former is applied to analysis of pharmaceutical preparations, a sample in the form of, for example, a tablet may be heated and sometimes burned by excitation light with strong energy. The latter type of FT-Raman spectroscopy cause fewer such problems than laser Raman spectroscopy and is considered to be more suitable for the analysis of pharmaceutical preparations. Therefore, in this study, we examined the state of APIs in pharmaceutical preparations using FT-Raman spectroscopy, speciˆcally the FT-Raman diŠerence spectrum between the spectrum of preparation and that of excipient. 
EXPERIMENTAL

Sample Materials
Alacepril tablets, spar‰oxa-cin tablets, powders, and nanoparticles, quinidine sulfate particles, and caŠeine sustained-release particles were provided by Dainippon Sumitomo Pharma Co., Ltd. The ingredients for core granules or coating (excipients), such as poly-L-lactic acid (average molecular weight 2290), were also provided by Dainippon Sumitomo Pharma Co., Ltd.
Apparatus and Measurement FT-Raman spectra were measured on a JASCO FT/IR 800 near FTinfrared spectrophotometer ( Jasco Co., Ltd., Tokyo, Japan) with an FT-Raman attachment ( Jasco RFT-800). Measurements were carried out using as the elicitation line of a PSU-S-1064 YAG laser (1064 nm, IE Optomech Ltd., UK) with laser power of about 1.0 W and resolution of 4 cm -1 (basically 100 scans). FT-Raman spectroscopy was conducted by placing a sample tablet or powder on a slide glass, while adjusting the position with the built-in video camera of the RFT-800.
For the measurement of diŠerence spectra, FT-Raman spectra of the pharmaceutical preparation, API, and a mixture of excipients were compared, and an independent band(s) speciˆc to the excipient and not present in the API spectrum was selected. Then the diŠerence spectrum was obtained by processing the data using four basic calculations of the arithmetic program in such a manner that the independent band of the excipient was eliminated from the spectrum of the sample. The resulting diŠerence spectrum and the original spectrum of the API were compared.
The FT-infrared spectra were measured on an Impact 400 infrared spectrophotometer (Nicoret Co., Madison, WI, USA) using the KBr disk or Nujol method as described in JP 15. KBr disks were prepared using a Jasco tabletting machine (10 mm diameter) and R-16B-02-type pressurizer (Riken Seiki Co., Ltd., Niigata, Japan).
Thermal analysis was performed on a Shimadzu DSC-50 DiŠerential Scanning Colorimeter (Shimadzu Co., Ltd., Kyoto, Japan).
Reagents Reagents such as hydrochloric acid and lactic acid were of reagent grade (Nacalai Tesque, Kyoto, Japan). KBr and liquid para‹n (Nujol) for IR were purchased from Jasco Co., Ltd. and Merk AG (Germany) and used without further processing.
RESULTS AND DISCUSSION
Alacepril Tablets, CaŠeine Sustained-release Particles, and Quinidine Sulfate Particles Figures 1, 2 , and 3 show the diŠerence spectrum, Raman spectrum of caŠeine hydrate, and Raman spectrum of alacepril tablets (40％ API in four excipients), caŠeine sustained-release particles (17％ active ingredient inˆve excipients), and quinidine sulfate particles (50％ API in three excipients), respectively. In every case, the diŠerence spectrum is almost identical to the spectrum of the API. These results indicate that the state of the API such as crystalline condition was not changed during the manufacturing process in these preparations and that the diŠerence spectrum is use- ful to obtain the FT-Raman spectrum of an API in a preparation. In the spectrum of quinidine sulfate, there is a peak at a diŠerent position from that in the diŠerence spectrum (indicated by an arrow); however, it should be unrelated to a change in state because the wave numbers of remaining peaks are almost the same. In particular, the wave numbers of the quinidine sulfate peaks in theˆngerprint region agree with those obtained from the diŠerence spectrum. Thus we concluded that quinidine sulfate also did not undergo a change in state during the manufacturing process.
Spar‰oxacin Tablets, Powders, and Nanoparticles Spar‰oxacin is a compound with the formula shown in Fig. 4 and has potent antibacterial activity. In this study, three formulations, i.e., tablets, powders, and nanoparticles, were examined because preparations containing spar‰oxacin as an API are generally in those forms. The tablets contain 63％ spar‰oxacin and 12 excipients, the powders 20％ spar‰oxacin and seven excipients, and the nanoparticles 8％ spar‰oxa-cin and one excipient, i.e., poly-L-lactic acid. Despite the relatively low concentration of the API, nanoparticles were expected to be suitable for the measurement of diŠerence spectra because they contain only one excipient. A good diŠerence spectrum of the nanoparticle preparation was obtained as expected.
The diŠerence spectra of the three preparations and Raman spectrum of spar‰oxacin are shown in Fig. 5 . The diŠerence spectrum of nanoparticles diŠers from the spectrum of spar‰oxacin. An especially marked diŠerence was found within the region indicated by a dashed line in Fig. 5 . In addition, there were diŠer-ences among spectra regarding wave number, even in the region subsequent to 1700 cm -1 . Accordingly, in nanoparticles, spar‰oxacin possibly underwent some changes due to procedures during manufacturing or measurement. We then investigated the causes of the changes.
First, we examined whether the elevated temperature due to heating during the manufacturing process of preparations or laser irradiation exercised any in‰uence on the state of spar‰oxacin. When spar‰oxa-cin was heated to 200°C and cooled and the FT-Raman and FT-IR spectra were measured, no changes were observed in the spectra. Spar‰oxacin was then examined using diŠerential scanning calorimetry (DSC), which only gave a peak at 269°C, correspond- ing to the melting point. It was therefore considered that crystal polymorphism was not present. These results indicate that the change in spectrum observed in the diŠerence spectrum of nanoparticles did not result from the alteration of the crystal form by heat. Further, a tablet was prepared by compressing spar‰oxacin bulk powder under pressure of 1000 N/ cm 2 , pulverizing the resultant tablet, and subjecting it to IR and FT-Raman spectroscopies. There were no changes due to pressurization in the spectrum. Then the in‰uence of moisture absorption during the manufacturing process or preservation was examined. Dry spar‰oxacin was kept in a desiccator saturated with water at room temperature for 1 week or 1 month and then the FT-Raman spectrum was measured. The resulting Raman spectrum was diŠerent from that of dry spar‰oxacin due to the formation of trihydrate, but it did not agree with the diŠerence spectrum either. It was therefore concluded that the change in spectrum observed in the diŠerence spectrum of nanoparticles did not result from moisture absorption.
The excipients used in these three forms of preparations were then compared. Tablets contained corn starch, hydroxypropyl cellulose, etc., and powders lactose, hydroxypropyl cellulose, talc, etc. However, nanoparticles contained only poly-L-lactic acid as an excipient, which showed the spectrum change for spar‰oxacin as described above. This led to the presumption that the interaction between spar‰oxacin and poly-L-lactic acid may be involved in the change in spectrum. Spar‰oxacin and poly-L-lactic acid were then pulverized in an agate mortar at diŠerent mixing ratios and subjected to Raman spectroscopy. Some of the resultant spectra are shown in Fig. 6 . As seen in Fig. 6 , the FT-Raman spectrum gradually changes as the ratio of spar‰oxacin to poly-L-lactic acid is lowered and becomes almost the same as the diŠerence spectrum of the preparation (nanoparticles) when the ratio decreases to 8％. This indicates that spar‰oxacin possibly interacts with poly-L-lactic acid in a concentration-dependent manner. Spar‰oxacin is a basic substance and poly-L-lactic acid contains a lower molecular-weight substance. Therefore spar‰oxacin could interact with the terminal carboxylic acid of poly-L-lactic acid. To conˆrm this assumption, interaction between spar‰oxacin and acids was investigated.
Spar‰oxacin was dissolved and mixed with 1 mol/l of hydrochloric acid, lactic acid, or a mixture thereof, evaporated to dryness under reduced pressure over sodium hydroxide, and subjected to measurement of FT-Raman and FT-IR spectra. The resulting FT-Raman spectra were in agreement with each other except for the region of 3200-2700 cm
, where the acid added aŠected the spectrum. When spar‰oxacin was treated with the mixture of hydrochloric and lactic acids, the FT-Raman spectrum in this region was consistent with the diŠerence spectrum shown in Fig. 5 (a). Figure 7 shows the FT-Raman spectrum of spar‰oxacin within the region of 1800-1000 cm -1 obtained by dissolving spar‰oxacin in hydrochloric acid, evaporating the solution in vacuo to dryness, and measuring the FT-Raman spectrum. Figure 7 indicates that the FT-Raman spectrum of spar‰oxacin after treatment with 1 mol/l of hydrochloric acid was almost in agreement with the diŠerence spectrum of nanoparticles. It was determined that spar‰oxacin underwent protonation when manufacturing nanoparticles.
In conclusion, the FT-Raman spectrum, a nondestructive analysis, is useful to obtain information regarding the state of APIs in preparations based on diŠerence spectra. The diŠerence spectrum of FT-Raman spectroscopy is expected to be utilized widely in theˆeld of quality control for crystalline conditions of pharmaceutical preparations. 
